AVN 67.13 Decreased By ▼ -3.17 (-4.51%)
BOP 9.83 Decreased By ▼ -0.21 (-2.09%)
CHCC 112.33 Decreased By ▼ -9.12 (-7.51%)
DCL 9.81 Decreased By ▼ -0.49 (-4.76%)
DGKC 103.04 Decreased By ▼ -3.56 (-3.34%)
EFERT 60.82 Decreased By ▼ -0.58 (-0.94%)
EPCL 40.10 Decreased By ▼ -1.05 (-2.55%)
FCCL 19.90 Decreased By ▼ -0.20 (-1%)
FFL 15.76 Decreased By ▼ -1.00 (-5.97%)
HASCOL 19.23 Decreased By ▼ -1.92 (-9.08%)
HBL 130.86 Decreased By ▼ -0.03 (-0.02%)
HUBC 78.53 Decreased By ▼ -0.92 (-1.16%)
HUMNL 7.60 Decreased By ▼ -0.20 (-2.56%)
JSCL 25.36 Decreased By ▼ -1.82 (-6.7%)
KAPCO 26.18 Decreased By ▼ -0.76 (-2.82%)
KEL 4.18 Decreased By ▼ -0.06 (-1.42%)
LOTCHEM 11.91 Decreased By ▼ -0.21 (-1.73%)
MLCF 35.98 Decreased By ▼ -1.24 (-3.33%)
OGDC 102.68 Decreased By ▼ -2.70 (-2.56%)
PAEL 32.56 Decreased By ▼ -2.03 (-5.87%)
PIBTL 12.15 Decreased By ▼ -0.63 (-4.93%)
PIOC 91.00 Decreased By ▼ -2.52 (-2.69%)
POWER 8.79 Decreased By ▼ -0.32 (-3.51%)
PPL 91.70 Decreased By ▼ -1.81 (-1.94%)
PSO 200.02 Decreased By ▼ -5.39 (-2.62%)
SNGP 61.00 Decreased By ▼ -1.60 (-2.56%)
STPL 13.05 Decreased By ▼ -0.34 (-2.54%)
TRG 52.26 Decreased By ▼ -2.49 (-4.55%)
UNITY 16.40 Decreased By ▼ -0.95 (-5.47%)
WTL 1.15 Decreased By ▼ -0.03 (-2.54%)
BR100 4,194 Decreased By ▼ -14.04 (-0.33%)
BR30 21,218 Decreased By ▼ -93.63 (-0.44%)
KSE100 40,677 Increased By ▲ 105.44 (0.26%)
KSE30 17,259 Increased By ▲ 53.29 (0.31%)
COVID-19 TOTAL DAILY
CASES 312,806 543
DEATHS 6,484 5
World

Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals

  • As the race to develop COVID-19 vaccines reach a decisive stage, pricing has come under increasing scrutiny
05 Aug 2020

Moderna Inc said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's vaccine candidate.

As the race to develop COVID-19 vaccines reach a decisive stage, with several candidates being tested in pivotal late-stage studies, pricing has come under increasing scrutiny.

"We will be responsible on price well below (its) value during the pandemic," Chief Executive Officer Stéphane Bancel said on a conference call, adding that larger volume agreements for its vaccine will be priced lower.

Last month, the U.S. government struck a deal for an experiment vaccine being developed by Pfizer and partner BioNTech SE that secures enough vaccine to inoculate 50 million Americans for about $40 a person. Moderna's two-dose vaccine regimen would cost between $64 and $74 per person.

Moderna, which has no drugs on the market, has received nearly $1 billion from the U.S. government under a plan to speed up vaccine development. It has not struck a supply agreement with the United States.